DiaSorin SpA

IT

DIAS

Health Care

94.94 ₽

Current price

Sell
94.94 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    320 / 663

  • Position in country

    402 / 520

  • Net income margin, %

    12.5

    -12.5

  • EBITDA margin, %

    34

    -2.5

  • Debt to Equity, %

    77.5

    15

  • Intangible assets and goodwill, %

    59.9

    3.9

  • Revenue CAGR 3Y, %

    9.2

    12.6

  • Revenue Y, % chg

    -12.7

    4.6

  • P/E

    30.2

    28.3

  • P/BV

    3

    1.7

  • P/S

    4.2

    3.7

  • EV/S

    4.9

    3.2

  • EV/EBITDA

    15

    -0.2

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    15.3

    66.5

  • Forward P/E

    23.5

    19.2

  • Dividend Yield, %

    1.3

    1.8

  • Forward Dividend Yield, %

    1.1

    0.2

  • Expected dividend per share

    0.9

    0

  • Payout Ratio, %

    36.7

    17.3

  • Dividend Ex Date

    2024-05-20

Get an analytical review of this company

Competitors

Ranks

  • Boston Scientific Corp

    00%

  • Intuitive Surgical Inc

    00%

  • El En SpA

    00%

  • Stryker Corp

    00%

  • Medtronic PLC

    00%

  • Edwards Lifesciences Corp

    00%

  • Siemens Healthineers AG

    00%

  • Abbott Laboratories

    00%

  • DiaSorin SpA

    00%

  • Becton Dickinson and Co

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Italy

  • Sector

    Health Care

  • Industry group

    Health Care Equipment & Services

  • Industry

    Health Care Equipment & Supplies

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    5201.8

  • Ticker

    DIAS.MI

  • ISIN

    IT0003492391

  • IPO date

    2007-07-19

  • Availability on Russian exchanges

    No

  • Reporting for

    2024-04-02

  • Date fact. publication of reports

    2023-12-31

Company Description

DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: